HRP20170324T1 - Ljudska antitijela visokog afiniteta za ljudski 2 proteazom aktivirani receptor - Google Patents
Ljudska antitijela visokog afiniteta za ljudski 2 proteazom aktivirani receptor Download PDFInfo
- Publication number
- HRP20170324T1 HRP20170324T1 HRP20170324TT HRP20170324T HRP20170324T1 HR P20170324 T1 HRP20170324 T1 HR P20170324T1 HR P20170324T T HRP20170324T T HR P20170324TT HR P20170324 T HRP20170324 T HR P20170324T HR P20170324 T1 HRP20170324 T1 HR P20170324T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- antigen
- binding fragment
- par
- disease
- Prior art date
Links
- 108010070503 PAR-2 Receptor Proteins 0.000 title 1
- 102000018402 Protease-activated receptor 2 Human genes 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 239000012634 fragment Substances 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 238000003776 cleavage reaction Methods 0.000 claims 5
- 230000007017 scission Effects 0.000 claims 5
- 230000003213 activating effect Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 claims 3
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 claims 3
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 102000004142 Trypsin Human genes 0.000 claims 2
- 108090000631 Trypsin Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 229940053128 nerve growth factor Drugs 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 239000012588 trypsin Substances 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 229940124790 IL-6 inhibitor Drugs 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 1
- 101100406879 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) par-2 gene Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000013467 fragmentation Methods 0.000 claims 1
- 238000006062 fragmentation reaction Methods 0.000 claims 1
- 230000016784 immunoglobulin production Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000010791 quenching Methods 0.000 claims 1
- 230000000171 quenching effect Effects 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 229940116269 uric acid Drugs 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (13)
1. Izolirano ljudsko antitijelo ili njegov antigen vezujući fragment koji se specifično vezuje za ljudski PAR-2 (SEQ ID NO:851) i stupa u interakciju s Val-42 i Asp-43 ljudskog PAR-2, naznačen time, što se antitijelo ili antigen vezujući fragment sastoji od regija koje određuju komplementarnost (CDR) koje sadrže sekvence aminokiselina HCDR1-HCDR2-HCDR3 / LCDR1-LCDR2-LCDR3 odabrane iz grupe koja se sastoji od: (a) SEQ ID NO:100-102-104 / 108-110-112; i (b) SEQ ID NO: 700-702-704 / 708-710-712.
2. Izolirano ljudsko antitijelo ili antigen vezujući fragment prema zahtjevu 1, naznačen time, što antitijelo ili antigen vezujući fragment također stupa u interakciju s jednim ili više ostataka odabranih iz grupe koja se sastoji od Ser-37, Leu-38, Ile-39, Gly-40 i Gly-44 ljudskog PAR-2.
3. Izolirano ljudsko antitijelo ili antigen vezujući fragment prema zahtjevu 1 ili 2, naznačen time, što antitijelo ili antigen vezujući fragment ne stupa u interakciju s Lys-41 ljudskog PAR-2.
4. Izolirano ljudsko antitijelo ili antigen vezujući fragment prema bilo kojem zahtjevu od 1 do 3, naznačeno time, što antitijelo ili antigen vezujući fragment stupa u interakciju sa Ser-37, Leu-38, Ile-39, Gly-40, Val-42 i Asp-43 ljudskog PAR-2, ali ne stupa u interakciju s Lys-41 ljudskog PAR-42.
5. Izolirano ljudsko antitijelo ili antigen vezujući fragment prema bilo kojem zahtjevu od 1 do 4, naznačen time, što antitijelo ili antigen vezujući fragment blokira kalanje tripsina ljudskog PAR-2 na aktivirajućem mjestu kalanja koje se nalazi na čvoru ostataka Arg-36 i Ser-37 ljudskog PAR-2.
6. Izolirano ljudsko antitijelo ili antigen vezujući fragment prema zahtjevu 5, naznačen time, što antitijelo ili antigen vezujući fragment ne blokira kalanje tripsina ljudskog PAR-2 na jednom ili više neaktivirajućih mjesta kalanja odabranih iz neaktivirajućeg mjesta kalanja koje se nalazi na čvoru ostataka Arg-31 i Ser-32 ljudskog PAR-2 i neakativirajućeg mjesta kalanja koje se nalazi na čvoru ostataka Lys-34 i Gly-35 ljudskog PAR-2.
7. Izolirano ljudsko antitijelo ili antigen vezujući fragment prema zahtjevu 1, naznačen time, što je spomenuto antitijelo ili antigen vezujući fragment odabran iz grupe koja se sastoji od: (a) antitijela koje sadrži varijabilnu regiju teškog lanca (HCVR) koja ima sekvencu aminokiseline SEQ ID NO:714 i varijabilnu regiju lakog lanca (LCVR) koja ima sekvencu aminokiseline SEQ ID NO:692; i (b) antitijela koje sadrži HCVR koja ima sekvencu aminokiseline SEQ ID NO:98 i LCVR koja ima sekvencu aminokiseline SEQ ID NO:106.
8. Farmaceutski pripravak koji sadrži antitijelo ili antigen vezujući fragment prema bilo kojem zahtjevu od 1 do 7 i farmaceutski prihvatljivi nosač ili otapalo.
9. Izolirano ljudsko antitijelo ili antigen vezujući fragment prema bilo kojem zahtjevu od 1 do 7 ili farmaceutski pripravak prema zahtjevu 8 za primjenu u načinu liječenja bolesnika, naznačen time, što spomenuti bolesnik ima jedan ili više simptoma ili indikatora bolesti ili poremećaja izazvanog aktivnošću PAR-2, pri čemu je bolest ili poremećaj izazvan aktivnošću PAR-2 bolest ili poremećaj odabran iz grupe koja se sastoji od boli, pruritusa, astme, reumatoidnog artritisa, fibroze, atopičnog dermatitisa, upalne bolesti crijeva, ulcerativnog kolitisa, pankreatitisa, čira, Chronove bolesti, raka i Nethertonove bolesti.
10. Izolirano antitijelo, antigen vezujući fragment ili pripravak prema zahtjevu 9, za primjenu prema zahtjevu 9, pri čemu se način dodatno sastoji od davanja bolesniku najmanje jednog dodatnog terapijski aktivnog sastojka odabranog iz grupe koja se sastoji od inhibitora IL-1, inhibitora IL-18, inhibitora IL-4, inhibitora receptora IL-4, inhibitora IL-6, inhibitora receptora IL-6, inhibitora nervnog faktora rasta (NGF), inhibitora faktora nekroze tumora (TNF) i inhibitora receptora TNF-a, inhibitora sinteze mokraćne kiseline i kortikosteroida.
11. Primjena izoliranog antitijela ili antigen vezujućeg fragmenta prema bilo kojem zahtjevu od 1 do 7 ili farmaceutskog pripravka prema zahtjevu 8, u proizvodnji lijeka za primjenu u liječenju bolesnika koji ima jedan ili više simptoma ili indikatora bolesti ili poremećaja izazvanog aktivnošću PAR-2, pri čemu je bolest ili poremećaj izazvan aktivnošću PAR-2 bolest ili poremećaj odabran iz grupe koja se sastoji od boli, pruritusa, astme, reumatoidnog artritisa, fibroze, atopičnog dermatitisa, upalne bolesti crijeva, ulcerativnog kolitisa, pankreatitisa, čira, Chronove bolesti, raka i Nethertonove bolesti.
12. Molekula nukleinske kiseline koja kodira antitijelo ili njegov antigen vezujući fragment prema bilo kojem zahtjevu od 1 do 7, rekombinantni vektor ekspresije koji nosi nukleinsku kiselinu ili stanica domaćin u koju je vektor uveden.
13. Način proizvodnje antitijela ili njegovog antigen vezujućeg fragmenta prema bilo kojem zahtjevu od 1 do 7, pri čemu se spomenuti način sastoji od kultiviranja stanice domaćina prema zahtjevu 12 u uvjetima koji omogućavaju proizvodnju antitijela i prikupljanje proizvedenih antitijela.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24078309P | 2009-09-09 | 2009-09-09 | |
| US24282109P | 2009-09-16 | 2009-09-16 | |
| US31783910P | 2010-03-26 | 2010-03-26 | |
| EP10754387.8A EP2475684B1 (en) | 2009-09-09 | 2010-09-08 | High affinity human antibodies to human protease-activated receptor-2 |
| PCT/US2010/048034 WO2011031695A1 (en) | 2009-09-09 | 2010-09-08 | High affinity human antibodies to human protease-activated receptor-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170324T1 true HRP20170324T1 (hr) | 2017-04-21 |
Family
ID=43063654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170324TT HRP20170324T1 (hr) | 2009-09-09 | 2017-02-27 | Ljudska antitijela visokog afiniteta za ljudski 2 proteazom aktivirani receptor |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8101724B2 (hr) |
| EP (1) | EP2475684B1 (hr) |
| JP (2) | JP5832435B2 (hr) |
| KR (1) | KR101766701B1 (hr) |
| CN (1) | CN102574923B (hr) |
| AR (1) | AR078346A1 (hr) |
| AU (1) | AU2010292342C1 (hr) |
| BR (1) | BR112012005338A2 (hr) |
| CA (1) | CA2773541A1 (hr) |
| CY (1) | CY1118714T1 (hr) |
| DK (1) | DK2475684T3 (hr) |
| ES (1) | ES2609780T3 (hr) |
| HK (1) | HK1166509A1 (hr) |
| HR (1) | HRP20170324T1 (hr) |
| HU (1) | HUE031725T2 (hr) |
| IL (1) | IL218501A (hr) |
| JO (1) | JO3246B1 (hr) |
| LT (1) | LT2475684T (hr) |
| MX (1) | MX2012002927A (hr) |
| MY (1) | MY159551A (hr) |
| NZ (1) | NZ599204A (hr) |
| PL (1) | PL2475684T3 (hr) |
| PT (1) | PT2475684T (hr) |
| SG (1) | SG178976A1 (hr) |
| SI (1) | SI2475684T1 (hr) |
| SM (1) | SMT201700102B (hr) |
| TW (1) | TWI492757B (hr) |
| UY (1) | UY32883A (hr) |
| WO (1) | WO2011031695A1 (hr) |
| ZA (1) | ZA201201730B (hr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| EP3434691A1 (en) | 2010-12-01 | 2019-01-30 | AlderBio Holdings LLC | Anti-ngf compositions and use thereof |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| MY173865A (en) | 2011-09-22 | 2020-02-25 | Amgen Inc | Cd27l antigen binding proteins |
| CA2924690A1 (en) | 2013-09-25 | 2015-04-02 | Vertex Pharmaceuticals Incorporated | Imidazopyridazines useful as inhibitors of the par-2 signaling pathway |
| US10519222B2 (en) * | 2014-02-28 | 2019-12-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region |
| US10548987B2 (en) | 2015-07-31 | 2020-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-drug conjugates for targeting CD56-positive tumors |
| EP3184547A1 (en) * | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| EP3374386B1 (en) * | 2015-11-13 | 2024-05-29 | Oasis Pharmaceuticals, LLC | Protease-activated receptor-2 modulators |
| JP2019534044A (ja) | 2016-11-08 | 2019-11-28 | クイル ピュージェット サウンド バイオセラピューティクス コーポレーション | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
| MX2019010802A (es) * | 2017-03-16 | 2019-10-30 | Medimmune Ltd | Anticuerpos anti-par2 y usos de los mismos. |
| CA3127025A1 (en) * | 2019-01-18 | 2020-07-23 | Janssen Biotech, Inc. | Gprc5d chimeric antigen receptors and cells expressing the same |
| WO2020201572A1 (en) | 2019-04-05 | 2020-10-08 | Université De Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
| CN114127109B (zh) * | 2019-05-30 | 2022-06-21 | 山东博安生物技术股份有限公司 | 靶向Claudin18.2的抗体或嵌合抗原受体 |
| CN114599351A (zh) * | 2019-11-01 | 2022-06-07 | 株式会社资生堂 | 以皮肤中的活性型par-2为指标的皮肤状态评价方法、par-2激活促进剂或抑制剂的筛选方法和par-2激活抑制剂 |
| WO2021202770A2 (en) * | 2020-03-31 | 2021-10-07 | Fred Hutchinson Cancer Research Center | Human anti-cd33 antibodies and uses thereof |
| EP4200018A1 (en) * | 2020-08-18 | 2023-06-28 | Cephalon LLC | Anti-par-2 antibodies and methods of use thereof |
| CA3228414A1 (en) * | 2021-09-02 | 2023-03-09 | Anthony DANIYAN | Anti-cd33 antibodies and uses thereof |
| AU2022340644A1 (en) * | 2021-09-02 | 2024-02-29 | Memorial Hospital For Cancer And Allied Diseases | Antigen recognizing receptors targeting cd33 and uses thereof |
| CN114181311B (zh) * | 2021-12-20 | 2023-06-20 | 华东师范大学 | 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用 |
| GB202204159D0 (en) * | 2022-03-24 | 2022-05-11 | Heptares Therapeutics Ltd | Antibodies |
| WO2024059336A1 (en) * | 2022-09-18 | 2024-03-21 | Memorial Sloan Kettering Cancer Center | Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716789A (en) * | 1993-07-26 | 1998-02-10 | Cor Therapeutics, Inc. | Method to determine ligands, agonist and antagonist of C140 receptor |
| AU5702298A (en) * | 1996-12-03 | 1998-06-29 | Abgenix, Inc. | Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom |
| US7888482B2 (en) * | 2006-02-10 | 2011-02-15 | Amgen Inc. | Antibodies that bind PAR-2 |
| WO2008086069A1 (en) * | 2007-01-03 | 2008-07-17 | The General Hospital Corporation | Methods of treating itch |
| CL2008001887A1 (es) * | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| KR20090082619A (ko) | 2008-01-28 | 2009-07-31 | 주식회사 알파크립텍 | 다프네틴을 함유하는 가려움증 또는 염증 개선용 화장료조성물 |
| AR070911A1 (es) | 2008-03-19 | 2010-05-12 | Regeneron Pharma | Uso de antagonistas del receptor par2 activado con proteasa |
| WO2010017086A1 (en) * | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Effectors of par-2 activation and their use in the modulation of inflammation |
| CN105285986A (zh) | 2009-06-18 | 2016-02-03 | 株式会社爱茉莉太平洋 | 含有栗子皮提取物的健康食品或药学组合物 |
| JP5739881B2 (ja) | 2009-06-18 | 2015-06-24 | 株式会社アモーレパシフィックＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ | 栗皮抽出物を含む化粧料組成物 |
| FR2947452B1 (fr) | 2009-07-01 | 2012-04-20 | Fabre Pierre Dermo Cosmetique | L-serine et/ou l-asparagine et/ou l-valine pour prevenir et/ou au traiter des reactions inflammatoires de la peau. |
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
-
2010
- 2010-08-23 JO JOP/2010/0293A patent/JO3246B1/ar active
- 2010-09-07 AR ARP100103275A patent/AR078346A1/es unknown
- 2010-09-08 SI SI201031386A patent/SI2475684T1/sl unknown
- 2010-09-08 SG SG2012015228A patent/SG178976A1/en unknown
- 2010-09-08 PL PL10754387T patent/PL2475684T3/pl unknown
- 2010-09-08 BR BR112012005338A patent/BR112012005338A2/pt not_active IP Right Cessation
- 2010-09-08 MY MYPI2012001005A patent/MY159551A/en unknown
- 2010-09-08 MX MX2012002927A patent/MX2012002927A/es active IP Right Grant
- 2010-09-08 HU HUE10754387A patent/HUE031725T2/en unknown
- 2010-09-08 JP JP2012528860A patent/JP5832435B2/ja not_active Expired - Fee Related
- 2010-09-08 CN CN201080047991.9A patent/CN102574923B/zh not_active Expired - Fee Related
- 2010-09-08 TW TW099130262A patent/TWI492757B/zh not_active IP Right Cessation
- 2010-09-08 US US12/877,133 patent/US8101724B2/en active Active
- 2010-09-08 DK DK10754387.8T patent/DK2475684T3/en active
- 2010-09-08 ES ES10754387.8T patent/ES2609780T3/es active Active
- 2010-09-08 WO PCT/US2010/048034 patent/WO2011031695A1/en active Application Filing
- 2010-09-08 PT PT107543878T patent/PT2475684T/pt unknown
- 2010-09-08 KR KR1020127008692A patent/KR101766701B1/ko active IP Right Grant
- 2010-09-08 CA CA2773541A patent/CA2773541A1/en not_active Abandoned
- 2010-09-08 NZ NZ599204A patent/NZ599204A/en not_active IP Right Cessation
- 2010-09-08 AU AU2010292342A patent/AU2010292342C1/en not_active Ceased
- 2010-09-08 EP EP10754387.8A patent/EP2475684B1/en active Active
- 2010-09-08 LT LTEP10754387.8T patent/LT2475684T/lt unknown
- 2010-09-09 UY UY0001032883A patent/UY32883A/es not_active Application Discontinuation
-
2011
- 2011-12-14 US US13/325,098 patent/US8425907B2/en active Active
-
2012
- 2012-03-06 IL IL218501A patent/IL218501A/en not_active IP Right Cessation
- 2012-03-09 ZA ZA2012/01730A patent/ZA201201730B/en unknown
- 2012-07-23 HK HK12107166.9A patent/HK1166509A1/zh not_active IP Right Cessation
-
2013
- 2013-03-26 US US13/850,644 patent/US9028819B2/en active Active
-
2015
- 2015-09-09 JP JP2015177339A patent/JP6055055B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-01 CY CY20171100144T patent/CY1118714T1/el unknown
- 2017-02-15 SM SM201700102T patent/SMT201700102B/it unknown
- 2017-02-27 HR HRP20170324TT patent/HRP20170324T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170324T1 (hr) | Ljudska antitijela visokog afiniteta za ljudski 2 proteazom aktivirani receptor | |
| JP7025356B2 (ja) | インターロイキン‐４受容体への結合のための抗体 | |
| JP6883591B2 (ja) | 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び使用 | |
| ES2737998T3 (es) | Moléculas de anticuerpo que tienen especificidad por OX40 humano | |
| ES2432173T3 (es) | Métodos de tratamiento de enfermedades inflamatorias crónicas usando un antagonista de GM-CSF | |
| ES2902063T3 (es) | Proteínas de unión a interleucina-13 | |
| Chen et al. | IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis | |
| ES2699716T3 (es) | Moléculas de anticuerpo que tienen especificidad por OX40 humano | |
| JP6830533B2 (ja) | 抗ｉｌ−３３抗体およびその使用 | |
| CA2790013C (en) | Fully human anti-tnf-.alpha. monoclonal antibody, preparation method and use thereof | |
| JP2013504577A5 (hr) | ||
| AU2015237275B2 (en) | Antibodies that bind human cannabinoid 1 (CB1) receptor | |
| KR20110110349A (ko) | Ｉｌ-1 결합 단백질 | |
| JP6469012B2 (ja) | インターロイキン−６に対する抗体およびその使用 | |
| US20150266954A1 (en) | Il-21 antibodies | |
| RU2020133229A (ru) | Антитела к klk5 и способы применения | |
| EP3443985B1 (en) | Treatment for neoplastic diseases | |
| CN104995210A (zh) | 类风湿关节炎的治疗 | |
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| Xu et al. | A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A | |
| JP6663910B2 (ja) | 抗ＴＮＦ−α抗体療法を受けた乾癬患者を治療するための方法 | |
| AU2019269131B2 (en) | Antibodies against LIF and dosage forms thereof | |
| CN113748130A (zh) | Tsg-6抗体和其用途 | |
| Du et al. | Molecular basis of recognition of human osteopontin by 23C3, a potential therapeutic antibody for treatment of rheumatoid arthritis | |
| CN105085679B (zh) | 全人源抗rankl抗体 |